Log in
Enquire now
‌

BIOLOGICAL MIMETICS, INC. SBIR Phase I Award, September 2023

A SBIR Phase I contract was awarded to Biological Mimetics in September, 2023 for $296,442.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health.

OverviewStructured DataIssuesContributors

Contents

sbir.gov/node/2509909
Is a
SBIR/STTR Awards
SBIR/STTR Awards
0

SBIR/STTR Award attributes

SBIR/STTR Award Recipient
‌
Biological Mimetics
0
Government Agency
0
Government Branch
National Institutes of Health
National Institutes of Health
0
Award Type
SBIR0
Contract Number (US Government)
1R43AI174497-01A10
Award Phase
Phase I0
Award Amount (USD)
296,4420
Date Awarded
September 20, 2023
0
End Date
August 31, 2025
0
Abstract

Abstract Methicillin-resistant Staphylococcus aureus is often considered the prototype hospital-acquired infection. In spite of the billions of dollars spent on preventive measures, estimates of the incidence are in the hundreds of thousands, with tens of thousands of people per year succumbing to disease in the USA alone. Prophylactic vaccines against S. aureus would have an enormous impact in the healthcare fight against antibiotic-resistant strains. In our previous studies, we used a novel method to generate next-generation whole-cell Staphylococcus vaccine candidates that resulted in high levels of clearance in a stringent biofilm model of infection. The method utilizes a manganese-decapeptide-phosphate (MDP) complex that has been adapted from the radiation-resistant bacterium, Deinococcus radiodurans. We propose to further develop this approach by directly comparing several of the identified vaccine candidates and next-generation modified versions in expanded studies. Candidates will be tested for stimulating protective immunity in biofilm pin implantation and abscess mouse models. Down- selected “best” candidates will also be tested in a S. aureus preexposure model as different immunogens (protein sets) circumvent deceptive immune imprinting. These experiments should allow us to categorically report which candidate proves the most efficacious in relevant animal models, and position a candidate ready for cross- protection, dosing, and toxicity studies to follow.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like BIOLOGICAL MIMETICS, INC. SBIR Phase I Award, September 2023

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.